The nomination committee’s proposal in respect of election of board members at the annual general meeting of Sedana Medical
The nomination committee of Sedana Medical AB (publ) (SEDANA: FN Stockholm) has presented its proposal in respect of election of board members at the annual general meeting to be held May 10, 2021. The nomination committee proposes re-election of all current board members, except for Sten Gibeck who has declined re-election, and new election of Claus Bjerre as ordinary member and vice chairman of the board of directors of Sedana Medical.
The nomination committee of Sedana Medical, which prior to the annual general meeting 2021 is constituted of Karl Tobieson (chairman of the nomination committee and appointed by Linc AB), Thomas Eklund (chairman of the board of directors), Malin Björkmo (appointed by Handelsbanken Fonder) and Caroline Sjösten (appointed by Swedbank Robur Fonder), has presented its proposal in respect of election of board members at the annual general meeting to be held May 10, 2021.
The nomination committee proposes re-election of Thomas Eklund, Bengt Julander, Ola Magnusson, Christoffer Rosenblad and Eva Walde, and new election of Claus Bjerre, as ordinary members of the board of directors of Sedana Medical for the period until the end of the next annual general meeting. Current board member Sten Gibeck has announced that he will not stand for re-election. The nomination committee further proposes re-election of Thomas Eklund as chairman of the board of directors and new election of Claus Bjerre as vice chairman of the board of directors of the company.
Claus Bjerre, who is proposed to be elected as new ordinary member and vice chairman of the board of directors of Sedana Medical, has long and broad experience within healthcare and Medtech. Claus has previously served as CEO and board member at Atos Medical and held several leadership positions at the Medtech-company Coloplast, including President, North America, and Senior Vice President, Emerging Markets. Claus is currently ordinary member of the board of directors and vice chairman of the board of Ellab and senior advisor at KKR & Co, Inc. Claus Bjerre holds an M.Sc. from the Copenhagen Business School and an MBA in Strategy and Finance from the UCLA Anderson School of Management.
”We would like to thank Sten for his solid and dedicated work as board member over the years, and also for his efforts and commitment in capacity as shareholder and one of the founders of Sedana Medical”, says Thomas Eklund, chairman of the board of directors of Sedana Medical.
“I am grateful and proud to have been part of the fantastic journey that Sedana Medical has made since we founded the company in 2005. It now feels natural to retire at my age, after 15 years on the board. It is fantastically satisfying to look back at what the board has achieved during these years. I continue to believe strongly in Sedana Medical and I will remain as major shareholder in the company”, says Sten Gibeck.
The nomination committee’s other proposals will be presented in the notice of the annual general meeting.
For additional information, please contact:
Karl Tobieson, chairman of the nomination committee
Mob: +46 70 935 85 74
E-mail: karl.tobieson@linc.se
Thomas Eklund, chairman of the board of directors
Mob: +46 70 824 20 25
E-mail: thomas.eklund@investorab.com
Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.
About Sedana Medical
Sedana Medical AB (publ) develops and sells the medical device AnaConDa for the administration of volatile anaesthetics. Through a combination of AnaConDa and the drug candidate Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated intensive care patients. The company has applied for marketing approval in Europe for Sedaconda and expects an approval in the second half of 2021.
Today, mechanically ventilated intensive care patients are sedated intravenously which leads to several challenges for both patients and care givers. Challenges that are solved by inhaled sedation. Globally, seven to eight million patients are estimated to be sedated in intensive care due to mechanical ventilation, evenly distributed between the US, Europe, and Asia. These patients are on average sedated three to four days. Sedana Medical estimates the total market potential to SEK 20-30 billion. Three years after marketing approval in Europe, Sedana Medical expects sales of SEK 500 million in Europe and an EBITDA margin of about 40 percent. The company has initiated processes to obtain marketing approval in the US in 2024 and in markets outside the EU.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics and Spain as well as external distributors in other parts of Europe, Australia, Canada, China, India, Israel, Japan, Mexico and South Korea. The company was founded in 2005 and is headquartered in Stockholm, Sweden, with medical device development in Ireland.